A Randomised, Multi-centre, Double-blind, Placebo-controlled, Single Ascending Dose, Multiple Dose Study to Assess Safety, Tolerability, PK, PD & Preliminary Efficacy of IV Doses of ONO-4685 in Patients With Plaque Psoriasis
Latest Information Update: 23 Aug 2024
At a glance
- Drugs ONO 4685 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
Most Recent Events
- 21 Aug 2024 Status changed from suspended to completed.
- 09 May 2024 Status changed from recruiting to suspended.
- 23 Aug 2023 Planned number of patients changed from 96 to 74.